Preferred Label : therapeutic use;
CISMeF acronym : TU;
Origin ID : Q000627;
UMLS CUI : C0039795;
Automatic exact mappings (from CISMeF team)
- False automatic mappings
- Metaterm(s)
- See also (suggested by CISMeF)
- Semantic type(s)
https://ansm.sante.fr/tableau-marr/methoxyflurane
2025
false
false
false
France
French
risk management
methoxyflurane
administration, inhalation
guidelines for drug use
methoxyflurane
methoxyflurane
Drug-Related side effects and adverse reactions
emergency treatment
pain
wounds and injuries
Post-traumatic pain
---
https://ansm.sante.fr/tableau-marr/levodopa-carbidopa
2025
false
false
false
France
French
risk management
carbidopa
levodopa
drug combinations
carbidopa, levodopa drug combination
Intestinal Route of Administration
patient care
nursing care
patient care planning
guidelines for drug use
patient education handout
continuity of patient care
patient care management
---
https://ansm.sante.fr/tableau-marr/icodextrine
2025
false
false
false
France
French
risk management
guidelines for drug use
peritoneal dialysis
blood glucose self-monitoring
Icodextrin
Blood glucose meter (physical object)
directory
patient education handout
---
https://ansm.sante.fr/tableau-acces-derogatoire/opdivo-nivolumab-solution-a-diluer-pour-perfusion-yervoy-ipilimumab-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
Malignant Pleural Mesothelioma
disease progression
Progressive Neoplastic Disease
infusions, intravenous
continuity of patient care
drug monitoring
carcinoma, non-small-cell lung
melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIIB Cutaneous Melanoma AJCC v7
technical report
---
https://ansm.sante.fr/tableau-marr/alpelisib
2025
false
false
false
France
French
guidelines for drug use
administration, oral
Drug-Related side effects and adverse reactions
alpelisib
Alpelisib
Alpelisib
continuity of patient care
Hyperglycaemic hyperosmolar nonketotic syndrome
hyperglycemia
ketosis
thiazoles
thiazoles
---
https://ansm.sante.fr/tableau-marr/esketamine
2025
false
false
false
France
French
guidelines for drug use
patients guideline
patient education handout
Esketamine
ketamine
dissociative disorders
administration, intranasal
antidepressive agents
risk management
esketamine
Esketamine
antidepressive agents
continuity of patient care
dissociation
Sleepiness
hypertension
Drug Misuse
ketamine
---
https://ansm.sante.fr/tableau-marr/fingolimod
2025
false
false
false
France
French
guidelines for drug use
patient education handout
Fingolimod Hydrochloride
pregnancy
administration, oral
immunosuppressive agents
immunosuppressive agents
fingolimod
continuity of patient care
Fingolimod Hydrochloride
teratogens
multiple sclerosis, relapsing-remitting
breast feeding
Fingolimod Hydrochloride
risk management
---
https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2025
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
thyroid cancer, medullary
drug information
selpercatinib
pyrazoles
pyridines
---
https://ansm.sante.fr/tableau-marr/fentanyl-3
2025
false
false
false
France
French
fentanyl
analgesics, opioid
risk management
narcotics
guidelines for drug use
patients guideline
administration, intranasal
nasal sprays
fentanyl
patient education handout
---
https://ansm.sante.fr/tableau-marr/fentanyl-5
2025
false
false
false
France
French
administration, sublingual
fentanyl
analgesics, opioid
risk management
narcotics
guidelines for drug use
patients guideline
fentanyl
Sublingual Tablet Dosage Form
---
https://ansm.sante.fr/tableau-acces-derogatoire/slenyto
2025
false
false
false
France
French
guidelines for drug use
melatonin
administration, oral
Delayed-Action preparations
child
adolescent
sleep disorders, circadian rhythm
melatonin
rett syndrome
angelman syndrome
tuberous sclerosis
technical report
---
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy
---
https://ansm.sante.fr/tableau-acces-derogatoire/venclyxto-10-mg-50mg-100-mg-comprimes-pellicules?#
2025
false
false
false
France
French
venetoclax
venetoclax
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
leukemia, myeloid, acute
precursor cell lymphoblastic Leukemia-Lymphoma
Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
leukemia, lymphocytic, chronic, B-Cell
drug information
Product containing only venetoclax in oral dose form (medicinal product form)
guidelines for drug use
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://ansm.sante.fr/tableau-acces-derogatoire/arikayce-liposomal
2025
false
false
false
France
French
guidelines for drug use
mycobacterium infections, nontuberculous
amikacin
liposomes
administration, inhalation
pneumonia, bacterial
anti-bacterial agents
Mycobacterium abscessus
amikacin
Infection caused by Mycobacteroides abscessus (disorder)
---
https://www.inesss.qc.ca/covid-19/autres-traitements/utilisation-des-antiviraux-pour-le-traitement-et-la-prophylaxie-de-linfluenza-chez-lenfant-et-ladulte-dans-le-contexte-de-la-covid-19.html
2025
false
false
false
Canada
coronavirus infections
pneumonia, viral
influenza, human
aged
influenza, human
risk factors
oseltamivir
zanamivir
continuity of patient care
practice guideline
guidelines for drug use
influenza, human
child
antiviral agents
adult
pandemics
COVID-19
---
https://ansm.sante.fr/dossiers-thematiques/cannabis-a-usage-medical
2025
false
false
false
false
France
medical marijuana
drug information
medical marijuana
---
https://ansm.sante.fr/tableau-acces-derogatoire/ospolot#
2025
false
false
false
France
French
guidelines for drug use
administration, oral
sulthiame
anticonvulsants
Continuous spikes and waves during sleep
continuity of patient care
sultiame
child
adolescent
adult
ospolot
epilepsy, rolandic
landau-kleffner syndrome
technical report
thiazines
---
https://ansm.sante.fr/tableau-acces-derogatoire/sirdalud
2025
false
false
false
France
French
summary of product characteristics
Product containing precisely tizanidine (as tizanidine hydrochloride) 4 milligram/1
each conventional release oral tablet (clinical drug)
tizanidine
muscle spasticity
drug information
clonidine
clonidine
---
https://www.cochrane.org/fr/CD010001/MENSTR_les-vasodilatateurs-medicaments-qui-elargissent-les-vaisseaux-sanguins-peuvent-ils-aider-les-femmes
2025
false
false
false
France
United Kingdom
infertility, female
vasodilator agents
treatment outcome
Evidence-Based medicine
vasodilator agents
review of literature
french abstract
---
https://ansm.sante.fr/tableau-marr/lutecium-177lu-oxodotreotide
2025
false
false
false
France
French
lutetium Lu 177 dotatate
risk management
patients guideline
lutetium Lu 177 dotatate
infusions, intravenous
radiotherapy
radiopharmaceuticals
radiopharmaceuticals
neuroendocrine tumors
lutetium (177Lu) oxodotreotide
drug information
organometallic compounds
octreotide
octreotide
organometallic compounds
octreotide
---
https://www.cochrane.org/fr/CD007872/CENTRALED_quels-sont-les-benefices-et-les-risques-de-lacide-tranexamique-pour-prevenir-les-saignements
2025
false
true
false
United Kingdom
France
treatment outcome
review of literature
french abstract
tranexamic acid
postpartum hemorrhage
---
https://www.cochrane.org/fr/CD006919/MENSTR_quels-medicaments-hormonaux-gnrha-fonctionnent-le-mieux-avec-les-hormones-de-stimulation-ovarienne
2025
false
true
false
France
United Kingdom
reproductive techniques, assisted
treatment outcome
gonadotropin-releasing hormone
review of literature
french abstract
gonadotropin-releasing hormone
---
https://www.cbip.be/fr/articles/4490?folia=4486
2025
false
false
false
Belgium
French
drug information
journal article
adrenergic beta-antagonists
myocardial infarction
treatment outcome
---
https://ansm.sante.fr/tableau-acces-derogatoire/elahere
2025
false
false
false
France
French
insurance, health, reimbursement
mirvetuximab soravtansine
mirvetuximab soravtansine
drug information
immunoconjugates
antibodies, monoclonal, humanized
maytansine
Antineoplastic Agents, Immunological
Folate Receptor Alpha Positive
ovarian neoplasms
peritoneal neoplasms
fallopian tube neoplasms
---
https://www.has-sante.fr/jcms/p_3594390/fr/vitrakvi-larotrectinib-sarcome-des-tissus-mous-cancer-des-glandes-salivaires-cancer-de-la-thyroide-non-medullaire
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Tyrosine Kinase Inhibitors
larotrectinib
TRK Inhibitor
nonmedullary thyroid carcinoma
adult
NTRK Fusion Gene Positive
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion (disorder)
evaluation of the transparency committee
salivary gland neoplasms
larotrectinib
sarcoma
thyroid neoplasms
---
https://www.has-sante.fr/jcms/p_3594381/fr/rystiggo-rozanolixizumab-myasthenie
2025
false
false
false
France
drug therapy, combination
adult
treatment outcome
insurance, health, reimbursement
immunosuppressive agents
rozanolixizumab
generalised myasthenia gravis with anti-acetylcholine receptor antibody
Adult-onset myasthenia gravis
infusions, subcutaneous
evaluation of the transparency committee
myasthenia gravis
rozanolixizumab
---
https://www.has-sante.fr/jcms/p_3594155/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
stomach neoplasms
esophageal neoplasms
treatment outcome
insurance, health, reimbursement
zolbetuximab
infusions, intravenous
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
adult
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
CLDN18.2 Positive
HER2/Neu Negative
evaluation of the transparency committee
adenocarcinoma
zolbetuximab
esophagogastric junction
---
https://www.has-sante.fr/jcms/p_3594378/fr/nilemdo-acide-bempedoique-dyslipidemie
2025
false
false
false
France
adult
risk
treatment outcome
insurance, health, reimbursement
bempedoic acid
nilemdo
Heart Disease Risk Factors
primary prevention
secondary prevention
cardiovascular diseases
Atherosclerotic Cardiovascular Disease
administration, oral
Product containing precisely bempedoic acid 180 milligram/1 each conventional release
oral tablet (clinical drug)
evaluation of the transparency committee
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
hypercholesterolemia
---
https://www.has-sante.fr/jcms/p_3594717/fr/carboxymaltose-ferrique-teva-carboxymaltose-ferrique-carence-martiale
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intravenous
infusions, intravenous
Product containing only ferric carboxymaltose in parenteral dose form (medicinal product
form)
iron, parenteral preparations
evaluation of the transparency committee
Iron Deficiencies
ferric carboxymaltose
---
https://www.has-sante.fr/jcms/p_3592810/fr/cuvitru-immunoglobuline-humaine-normale-immunoglobuline
2025
false
false
false
France
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
immunoglobulins, normal human, for extravascular adm.
immunologic factors
adult
child
adolescent
immunologic deficiency syndromes
Secondary immune deficiency disorder (disorder)
Primary Immunodeficiency Diseases
evaluation of the transparency committee
immunoglobulins
---
https://www.has-sante.fr/jcms/p_3594402/fr/hyqvia-immunoglobuline-humaine-normale-plasmatique-polyradiculonevrite-inflammatoire-demyelinisante-chronique-pidc
2025
false
false
false
France
infusions, subcutaneous
treatment outcome
insurance, health, reimbursement
immunoglobulins, normal human, for extravascular adm.
adult
adolescent
child
immunologic factors
infant, newborn
infant
evaluation of the transparency committee
polyradiculoneuropathy, chronic inflammatory demyelinating
immunoglobulins
---
https://www.has-sante.fr/jcms/p_3594375/fr/tepadina-thiotepa-greffe
2025
false
false
false
France
Product containing only thiotepa in parenteral dose form (medicinal product form)
infusions, intravenous
treatment outcome
insurance, health, reimbursement
transplantation conditioning
transplantation, autologous
transplantation, homologous
intense chemotherapy program
evaluation of the transparency committee
thiotepa
hematopoietic stem cell transplantation
---
https://ansm.sante.fr/tableau-marr/isatuximab
2025
false
false
false
France
French
risk management
isatuximab
guideline
patient education handout
blood transfusion
indirect coombs test
Laboratory test interference
---
https://www.has-sante.fr/jcms/p_3594961/fr/spevigo-spesolimab-psoriasis-pustuleux-generalise-ppg-chez-l-adulte-et-l-adolescent
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
spesolimab
Generalized pustular psoriasis
Generalized pustular psoriasis flare
evaluation of the transparency committee
adolescent
spesolimab
adult
psoriasis
---
https://www.has-sante.fr/jcms/p_3597499/fr/hympavzi-marstacimab-hemophilie
2025
false
false
false
France
hemorrhage
evaluation of the transparency committee
marstacimab
hemophilia A
---
https://www.cbip.be/fr/articles/4504?folia=4503
2025
false
false
false
Belgium
French
antidepressive agents
bipolar disorder
time
Long-term drug therapy (procedure)
journal article
drug information
dysthymic disorder
---
https://ansm.sante.fr/tableau-acces-derogatoire/acalabrutinib-100-mg-gelules#
2025
false
false
false
France
French
acalabrutinib
drug information
---
https://ansm.sante.fr/informations-de-securite/entonox-170-bar-gaz-pour-inhalation-en-bouteille-risque-de-defaut-dadministration-lie-au-blocage-du-robinet-par-le-froid-lors-dune-administration-avec-un-debit-continu-superieur-a-8-l-min-branchement-a-partir-de-lolive-de-sortie-du-robinet
2025
false
false
false
France
French
pharmacovigilance note
oxygen
nitrous oxide
drug combinations
meopa
nitrous oxide, combinations
Gas Output Problem
---
https://www.has-sante.fr/jcms/p_3597606/fr/krazati-adagrasib-cancer-bronchique-non-a-petites-cellules-avance-cbnpc
2025
false
false
false
France
bronchial neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic agents
adagrasib
adult
KRAS G12C Inhibitor
KRAS NP_004976.2:p.G12C
evaluation of the transparency committee
carcinoma, non-small-cell lung
adagrasib
---
https://www.has-sante.fr/jcms/p_3597161/fr/nicorettespray-/-nicorettespray-fruits-rouges-nicotine-sevrage-tabagique
2025
false
false
false
France
tobacco use disorder
administration, buccal
oral sprays
treatment outcome
insurance, health, reimbursement
adult
nicotine
evaluation of the transparency committee
nicotine
smoking cessation
---
https://www.has-sante.fr/jcms/p_3598534/fr/voxzogo-vosoritide-achondroplasie-chez-les-patients-ages-de-4-mois-a-moins-de-5-ans
2025
false
false
false
France
infant
child
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
vosoritide
evaluation of the transparency committee
vosoritide
achondroplasia
---
https://www.has-sante.fr/jcms/p_3556159/fr/dupixent-dupilumab-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
injections, subcutaneous
evaluation of the transparency committee
dupilumab
pulmonary disease, chronic obstructive
---
https://ansm.sante.fr/tableau-acces-derogatoire/zanidatamab
2025
false
false
false
France
French
infusions, intravenous
zanidatamab
drug information
summary of product characteristics
package leaflet
adult
biliary tract neoplasms
HER2 positive biliary tract cancer
HER2/Neu Expression by Immunohistochemistry 3+
zanidatamab
Locally Advanced Bile Duct Carcinoma
Metastatic Bile Duct Carcinoma
Unresectable Bile Duct Carcinoma
guidelines for drug use
---
https://ansm.sante.fr/tableau-marr/sel-de-fer-injectable
2025
false
false
false
France
French
risk management
iron compounds
iron, parenteral preparations
patient education handout
guidelines for drug use
injections, intravenous
infusions, intravenous
iron compounds
anaphylaxis
drug hypersensitivity
Drug-Related side effects and adverse reactions
---
https://www.has-sante.fr/jcms/p_3577039/fr/primaquine-sanofi-primaquine-phosphate-paludisme
2025
false
false
false
France
Product containing precisely primaquine (as primaquine phosphate) 15 milligram/1 each
conventional release oral tablet (clinical drug)
insurance, health, reimbursement
treatment outcome
adult
adolescent
child
recurrence
antimalarials
Vivax Malaria
Ovale malaria (disorder)
primaquine
evaluation of the transparency committee
malaria
primaquine phosphate
primaquine
---
https://www.has-sante.fr/jcms/p_3577021/fr/vabysmo-faricimab-oedeme-maculaire-secondaire-a-une-occlusion-de-branche-veineuse-retinienne-obvr-ou-de-la-veine-centrale-de-la-retine-ovcr
2025
false
false
false
France
faricimab
vision disorders
Central Retinal Vein Occlusion
intravitreal injections
adult
evaluation of the transparency committee
macular edema
faricimab
retinal vein occlusion
Branch Vein Occlusion
---
https://www.has-sante.fr/jcms/p_3576108/fr/adzynma-apadamtase-alfa-purpura-thrombotique-thrombocytopenique-congenital-pttc-pediatrie
2025
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Apadamtase Alfa
guidelines for drug use
apadamtase alfa and cinaxadamtase alfa
Cinaxadamtase Alfa
enzyme replacement therapy
ADAMTS13 protein, human
injections, intravenous
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
congenital thrombotic thrombocytopenic purpura
---
https://www.has-sante.fr/jcms/p_3542801/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique
2025
false
false
false
France
blinatumomab
antineoplastic agents
adult
treatment outcome
insurance, health, reimbursement
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Measurable Residual Disease Negativity
consolidation chemotherapy
evaluation of the transparency committee
precursor cell lymphoblastic Leukemia-Lymphoma
blinatumomab
---
https://ansm.sante.fr/tableau-marr/mavacamten
2025
false
false
false
France
French
risk management
mavacamten
mavacamten
mavacamten
administration, oral
patients guideline
guidelines for drug use
fetus
pregnancy
embryo
drug interactions
heart failure, systolic
Fetal exposure to drug (situation)
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors
Cytochrome P450 family 2 subfamily C member 19 intermediate metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 ultra-rapid metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 poor metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 normal metabolizer (finding)
patient education handout
---
https://ansm.sante.fr/tableau-acces-derogatoire/avastin-r-25-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
Bevacizumab
drug information
guidelines for drug use
intravitreal injections
macular degeneration
Neovascular age-related macular degeneration
---
https://ansm.sante.fr/tableau-acces-derogatoire/balversa-erdafitinib
2025
false
false
false
France
French
drug information
erdafitinib
administration, oral
erdafitinib
---
https://ansm.sante.fr/tableau-acces-derogatoire/sotatercept
2025
false
false
false
France
French
sotatercept
recombinant fusion proteins
Pulmonary Arterial Hypertension
drug information
Pulmonary arterial hypertension WHO functional class III
Pulmonary arterial hypertension WHO functional class II
insurance, health, reimbursement
adult
sotatercept
---
https://ansm.sante.fr/tableau-acces-derogatoire/casgevy
2025
false
false
false
France
French
biological products
exagamglogene autotemcel
Exagamglogene Autotemcel
risk management
beta-Thalassemia
Transfusion Dependent Beta Thalassemia
adolescent
adult
Cell positive for CD34 antigen (cell)
infusions, intravenous
young adult
anemia, sickle cell
drug information
---
https://ansm.sante.fr/tableau-marr/fentanyl-6
2025
false
false
false
France
French
fentanyl
Fentanyl Citrate
risk management
administration, sublingual
guidelines for drug use
fentanyl
patients guideline
adult
breakthrough pain
drug prescriptions
narcotics
Cancer Pain
---
https://ansm.sante.fr/tableau-acces-derogatoire/tak-755
2025
false
false
false
France
French
Apadamtase Alfa
congenital thrombotic thrombocytopenic purpura
enzyme replacement therapy
ADAMTS13 Protein
purpura, thrombotic thrombocytopenic
child
adolescent
adult
drug information
---
https://ansm.sante.fr/tableau-acces-derogatoire/altuvoct
2025
false
false
false
France
French
Efanesoctocog Alfa
drug information
hemophilia A
hemorrhage
hemorrhage
---
https://ansm.sante.fr/tableau-acces-derogatoire/omaveloxolone
2025
false
false
false
France
French
insurance, health, reimbursement
Omaveloxolone
administration, oral
adult
adolescent
friedreich ataxia
drug information
omaveloxolone
---
https://ansm.sante.fr/tableau-marr/lomitapide
2025
false
false
false
France
French
risk management
lomitapide
lomitapide
patient education handout
guideline
drug interactions
anticholesteremic agents
lomitapide
anticholesteremic agents
administration, oral
---
https://ansm.sante.fr/tableau-acces-derogatoire/rybrevant
2025
false
false
false
France
French
summary of product characteristics
amivantamab
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor
exon 20 insertion mutations
carcinoma, non-small-cell lung
guidelines for drug use
package leaflet
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
EGFR Exon 20 Insertion Mutation
---
https://ansm.sante.fr/tableau-marr/eliglustat
2025
false
false
false
France
French
risk management
eliglustat
guidelines for drug use
drug interactions
patients guideline
eliglustat
---
https://ansm.sante.fr/tableau-acces-derogatoire/elranatamab
2025
false
false
false
France
French
Elranatamab
multiple myeloma
adult
Relapsed/refractory multiple myeloma
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
antibodies, monoclonal
drug information
elranatamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/jakavi-5-mg-comprime
2025
false
false
false
France
French
insurance, health, reimbursement
ruxolitinib phosphate
ruxolitinib
administration, oral
graft vs host disease
Steroid Refractory Graft Versus Host Disease
acute disease
chronic disease
pharmaceutical solutions
child
guidelines for drug use
summary of product characteristics
package leaflet
tablets
---
https://ansm.sante.fr/tableau-acces-derogatoire/zilucoplan#
2025
false
false
false
France
French
drug information
injections, subcutaneous
zilucoplan
generalised myasthenia gravis with anti-acetylcholine receptor antibody
adult
myasthenia gravis, generalized
Acetylcholine receptor antibody (substance)
zilucoplan
technical report
---
https://ansm.sante.fr/tableau-acces-derogatoire/maribavir
2025
false
false
false
France
French
maribavir
drug information
administration, oral
maribavir
cytomegalovirus infections
adult
Refractory Cytomegalovirus Infection
antiviral agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/vutrisiran
2025
false
false
false
France
French
Vutrisiran
drug information
amyloidosis, hereditary, Transthyretin-Related
vutrisiran
---
https://ansm.sante.fr/tableau-acces-derogatoire/upstaza
2025
false
false
false
France
French
Eladocagene Exuparvovec
drug information
infant
Aromatic-L-Amino-Acid decarboxylases
Aromatic-L-Amino-Acid Decarboxylase
aromatic amino acid decarboxylase deficiency
technical report
---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2025
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet
antineoplastic combined chemotherapy protocols
---
https://www.has-sante.fr/jcms/p_3417653/fr/livtencity-maribavir-infection-a-cmv
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
maribavir
cytomegalovirus infections
antiviral agents
Product containing only maribavir (medicinal product)
adult
organ transplantation
hematopoietic stem cell transplantation
Refractory Cytomegalovirus Infection
administration, oral
evaluation of the transparency committee
maribavir
---
https://ansm.sante.fr/tableau-acces-derogatoire/idefirix
2025
false
false
false
France
French
infusions, intravenous
imlifidase
Imlifidase
kidney transplantation
Anti-HLA hyperimmunization
drug information
---
https://ansm.sante.fr/tableau-marr/idecabtagene-vicleucel
2025
false
false
false
France
French
guidelines for drug use
popular works
risk management
idecabtagene vicleucel
idecabtagene vicleucel
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
drug compounding
idecabtagene vicleucel
gene therapy
immunotherapy, adoptive
idecabtagene vicleucel
continuity of patient care
nervous system diseases
infusions, intravenous
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
Cytokine Release Syndrome
Cytokine Release Syndrome
signs and symptoms
defrosting
---
https://ansm.sante.fr/tableau-marr/aflibercept
2025
false
false
false
France
French
guidelines for drug use
patients guideline
aflibercept
recombinant fusion proteins
receptors, vascular endothelial growth factor
Drug-Related side effects and adverse reactions
signs and symptoms
intravitreal injections
video recording
intravitreal injections
sound
---
https://ansm.sante.fr/tableau-acces-derogatoire/enfortumab-vedotin-padcev
2025
false
false
false
France
French
drug information
insurance, health, reimbursement
enfortumab vedotin
enfortumab vedotin
Locally Advanced Urothelial Carcinoma
carcinoma, transitional cell
urologic neoplasms
Metastatic Urothelial Carcinoma
neoplasm metastasis
Refractory Urothelial Carcinoma
infusions, intravenous
antineoplastic agents
antineoplastic combined chemotherapy protocols
pembrolizumab
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
---
https://ansm.sante.fr/tableau-acces-derogatoire/ursofalk-250-mg-5-ml-suspension-buvable
https://ansm.sante.fr/tableau-acces-derogatoire/ursofalk-250-mg-5-ml-suspension-buvable#
2025
false
false
false
France
French
ursodeoxycholic acid
guidelines for drug use
cystic fibrosis
Hepatobiliary Disorders
administration, oral
infant
child
technical report
---
https://ansm.sante.fr/actualites/amoxicilline-des-recommandations-pour-contribuer-a-garantir-la-couverture-des-besoins-des-patients
2025
false
false
false
France
French
amoxicillin
guidelines for drug use
amoxicillin
administration, oral
infant
child
amoxicillin
amoxicillin-potassium clavulanate combination
amoxicillin-potassium clavulanate combination
amoxicillin and beta-lactamase inhibitor
---
https://ansm.sante.fr/tableau-acces-derogatoire/lioresal-10-mg-comprime-secable
2025
false
false
false
France
French
drug information
baclofen
Product containing precisely baclofen 1 milligram/1 milliliter conventional release
oral solution (clinical drug)
contracture
muscle spasticity
administration, oral
gastroesophageal reflux
Unable to swallow tablet (finding)
---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2025
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/xenpozyme#
2025
false
false
false
France
French
drug information
olipudase alfa
olipudase alfa
enzyme replacement therapy
child
adolescent
adult
niemann-pick diseases
---
https://ansm.sante.fr/tableau-acces-derogatoire/enhertu-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
Metastatic Gastric Adenocarcinoma
stomach neoplasms
adenocarcinoma
neoplasm metastasis
Locally Advanced Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
HER2/Neu Positive
trastuzumab deruxtecan
infusions, intravenous
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
Metastatic HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm recurrence, local
---
https://ansm.sante.fr/tableau-acces-derogatoire/imfinzi-50-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
durvalumab
guidelines for drug use
Unresectable Biliary Tract Carcinoma
antineoplastic combined chemotherapy protocols
Metastatic Biliary Tract Carcinoma
durvalumab
adult
Cisplatin/Durvalumab/Gemcitabine Regimen
infusions, intravenous
cisplatin
carcinoma, hepatocellular
carcinoma, non-small-cell lung
small cell lung carcinoma
bronchial neoplasms
---
https://ansm.sante.fr/tableau-marr/lauromacrogol-400
2025
false
false
false
France
French
risk management
guidelines for drug use
Polidocanol
polidocanol
patients guideline
Polidocanol
Drug-Related side effects and adverse reactions
continuity of patient care
Polidocanol
drug compounding
---
https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2025
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease
---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2025
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care
---
https://ansm.sante.fr/tableau-acces-derogatoire/imcivree#
2025
false
false
false
France
French
setmelanotide
adult
adolescent
child
obesity
obesity
bardet-biedl syndrome
continuity of patient care
drug monitoring
product surveillance, postmarketing
setmelanotide
injections, subcutaneous
guidelines for drug use
package leaflet
summary of product characteristics
technical report
---
https://ansm.sante.fr/tableau-acces-derogatoire/lutathera
2025
false
false
false
France
French
infusions, intravenous
drug information
lutetium (177Lu) oxodotreotide
lutetium Lu 177 dotatate
radiopharmaceuticals
guidelines for drug use
Pheochromocytoma-paraganglioma
pheochromocytoma
Metastatic Lung Neuroendocrine Tumor
bronchial neoplasms
neoplasm metastasis
Thymic neuroendocrine tumor
neuroendocrine tumors
thymus neoplasms
Metastatic Thymus Neuroendocrine Neoplasm
meningioma
Somatostatin Receptor Positive
Somatostatin Receptor 2 Positive
technical report
---
https://ansm.sante.fr/tableau-marr/adrenaline-3
2025
false
false
false
France
French
risk management
epinephrine
guidelines for drug use
self administration
injections, intramuscular
epinephrine
anaphylaxis
patients guideline
drug storage
video recording
epinephrine
---
https://ansm.sante.fr/tableau-atu-rtu/primaquine-sanofi-15-mg-comprime-pellicule
2025
false
false
false
France
French
primaquine
primaquine
malaria, vivax
Ovale malaria (disorder)
recurrence
administration, oral
antimalarials
pneumonia, pneumocystis
Product containing precisely primaquine (as primaquine phosphate) 15 milligram/1 each
conventional release oral tablet (clinical drug)
Product containing precisely primaquine (as primaquine phosphate) 7.5 milligram/1
each conventional release oral tablet (clinical drug)
technical report
drug information
---
https://www.ema.europa.eu/en/medicines/human/EPAR/wezenla
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
fruquintinib
fruquintinib
administration, oral
drug approval
europe
VEGFR Tyrosine Kinase Inhibitor
fruquintinib
VEGFR Tyrosine Kinase Inhibitor
receptors, vascular endothelial growth factor
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
risk management
product surveillance, postmarketing
antineoplastic agents
antineoplastic agents
neoplasm metastasis
colorectal neoplasms
Metastatic Colorectal Carcinoma
Refractory Colorectal Carcinoma
adult
drug interactions
aged
pregnancy
breast feeding
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tofidence
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
tocilizumab
tocilizumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/buprenorphine-neuraxpharm
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
buprenorphine
buprenorphine
risk management
drug approval
europe
buprenorphine
opiate substitution treatment
opioid-related disorders
adult
adolescent
administration, sublingual
Sublingual Film Dosage Form
Opioid Receptor Agonist
narcotic antagonists
drug interactions
pregnancy
breast feeding
prescription drug misuse
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tuznue
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Trastuzumab
Trastuzumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/vevizye
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
cyclosporine
cyclosporine
ciclosporin
drug approval
europe
risk management
administration, ophthalmic
keratoconjunctivitis sicca
Product containing only ciclosporin in ocular dose form (medicinal product form)
adult
pregnancy
breast feeding
Calcineurin Inhibitors
Calcineurin Inhibitors
drug evaluation, preclinical
ophthalmic solutions
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ituxredi
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Rituximab
Rituximab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/epruvy
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ranibizumab
Ranibizumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/axitinib-accord
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Axitinib
Axitinib
drugs, generic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
toripalimab
toripalimab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/anzupgo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
delgocitinib
delgocitinib
---
https://www.ema.europa.eu/en/medicines/human/EPAR/vyloy
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
zolbetuximab
zolbetuximab
orphan drug production
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kayfanda
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
odevixibat
odevixibat
---
https://www.ema.europa.eu/en/medicines/human/EPAR/iqirvo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
administration, oral
elafibranor
elafibranor
orphan drug production
---
https://www.ema.europa.eu/en/medicines/human/EPAR/hympavzi
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
marstacimab
marstacimab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/truqap
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
capivasertib
capivasertib
---
https://www.ema.europa.eu/en/medicines/human/EPAR/altuvoct
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Efanesoctocog Alfa
Efanesoctocog Alfa
orphan drug production
---
https://www.ema.europa.eu/en/medicines/human/EPAR/elahere
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
mirvetuximab soravtansine
mirvetuximab soravtansine
---
https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-teva
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drugs, generic
treatment outcome
pomalidomide
pomalidomide
---
https://www.has-sante.fr/jcms/p_3508311/fr/winrevair-sotatercept-hypertension-arterielle-pulmonaire
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug therapy, combination
sotatercept
evaluation of the transparency committee
Pulmonary Arterial Hypertension
sotatercept
---
https://www.has-sante.fr/jcms/p_3576525/fr/ogsiveo-nirogacestat-tumeurs-desmoides
2025
false
false
false
France
nirogacestat
treatment outcome
insurance, health, reimbursement
Tumor Progression
Refractory Desmoid Fibromatosis
adult
administration, oral
Gamma Secretase Inhibitors
nirogacestat
evaluation of the transparency committee
ogsiveo
Desmoid Tumors
---
https://www.has-sante.fr/jcms/p_3576557/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
adult
Fluoropyrimidine
platinum salt, nos
Gastric Adenocarcinoma
stomach neoplasms
Gastroesophageal Junction Adenocarcinoma
esophageal neoplasms
HER2/Neu Negative
CLDN18.2 Positive
infusions, intravenous
zolbetuximab
evaluation of the transparency committee
zolbetuximab
adenocarcinoma
---
https://www.has-sante.fr/jcms/p_3574250/fr/eladynos-abaloparatide-osteoporose
2025
false
false
false
France
abaloparatide
Product containing only abaloparatide in parenteral dose form (medicinal product form)
treatment outcome
insurance, health, reimbursement
osteoporotic fractures
History of vertebral fracture (situation)
History of osteoporotic fracture (situation)
injections, subcutaneous
bone density conservation agents
evaluation of the transparency committee
osteoporosis, postmenopausal
abaloparatide
---
https://www.has-sante.fr/jcms/p_3576426/fr/viperfav-fragment-f-ab-2-d-immunoglobulines-equines-antivenimeuses-de-viperes-europeennes-vipera-aspis-vipera-berus-vipera-ammodytes-immunoglobulines
2025
false
false
false
France
immunoglobulin fab fragments
treatment outcome
insurance, health, reimbursement
snake venom antiserum
snake bites
Snakebite envenomation
infusions, intravenous
evaluation of the transparency committee
european viper
---
https://www.has-sante.fr/jcms/p_3577033/fr/glycerophosphate-de-sodium-kabi-glycerophosphate-de-sodium-anhydre-solution-d-electrolytes
2025
false
false
false
France
Sodium Glycerophosphate Anhydrous
treatment outcome
insurance, health, reimbursement
adult
infant, newborn
infant
child
adolescent
hypophosphatemia
Phosphorus supplement therapy (regime/therapy)
parenteral nutrition
infusions, intravenous
sodium glycerophosphate
evaluation of the transparency committee
sodium glycerophosphate
electrolytes
alpha-glycerophosphoric acid
glycerophosphates
---
https://www.has-sante.fr/jcms/p_3577027/fr/nomanesit-sumatriptan/naproxene-migraine
2025
false
false
false
France
sumatriptan-naproxen
sumatriptan succinate
naproxen sodium
administration, oral
insurance, health, reimbursement
treatment outcome
migraine without aura
sumatriptan and naproxen
adult
drug combinations
evaluation of the transparency committee
migraine with aura
---
https://www.has-sante.fr/jcms/p_3577030/fr/benlysta-belimumab-lupus-systemique-actif
2025
false
false
false
France
belimumab
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
belimumab
---
https://www.has-sante.fr/jcms/p_3574253/fr/ventoline-salbutamol-asthme
2025
false
false
false
France
injections, subcutaneous
acute disease
evaluation of the transparency committee
albuterol
asthma
---
https://www.has-sante.fr/jcms/p_3576262/fr/jakavi-ruxolitinib-maladie-du-greffon-pediatrie
2025
false
false
false
France
administration, oral
pharmaceutical solutions
graft vs host disease
child
ruxolitinib
Janus Kinase Inhibitors
evaluation of the transparency committee
ruxolitinib
---
https://www.has-sante.fr/jcms/p_3577036/fr/kalydeco-ivacaftor-mucoviscidose
2025
false
false
false
France
infant
treatment outcome
insurance, health, reimbursement
administration, oral
ivacaftor
evaluation of the transparency committee
cystic fibrosis
ivacaftor
---
https://www.has-sante.fr/jcms/p_3576423/fr/pheburane-phenylbutyrate-de-sodium-desordres-du-cycle-de-l-uree
2025
false
false
false
France
pharmaceutical solutions
administration, oral
treatment outcome
insurance, health, reimbursement
sodium phenylbutyrate
4-phenylbutyric acid
carbamoyl-phosphate synthase i deficiency disease
citrullinemia
ornithine carbamoyltransferase deficiency disease
evaluation of the transparency committee
phenylbutyrates
4-phenylbutyric acid, sodium salt
---
https://www.has-sante.fr/jcms/p_3578491/fr/jemperli-dostarlimab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
dostarlimab
antineoplastic combined chemotherapy protocols
Carboplatin/Dostarlimab/Paclitaxel Regimen
carboplatin
paclitaxel
Mismatch Repair Deficiency
High-Frequency Microsatellite Instability
adult
infusions, intravenous
antineoplastic agents
evaluation of the transparency committee
dostarlimab
endometrial neoplasms
---
https://www.has-sante.fr/jcms/p_3578966/fr/briumvi-ublituximab-sclerose-en-plaques
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
ublituximab
adult
infusions, intravenous
evaluation of the transparency committee
multiple sclerosis, relapsing-remitting
ublituximab
---
https://www.has-sante.fr/jcms/p_3578470/fr/amikacine-panpharma-amikacine-antibacterien-aminoside
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
amikacin
Product containing precisely amikacin (as amikacin sulfate) 250 milligram/1 milliliter
conventional release solution for injection (clinical drug)
infusions, intravenous
injections, intramuscular
evaluation of the transparency committee
anti-bacterial agents
amikacin
---
https://www.has-sante.fr/jcms/p_3585759/fr/balversa-erdafitinib-carcinome-urothelial
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
erdafitinib
Product containing only erdafitinib in oral dose form (medicinal product form)
administration, oral
FGFR Inhibitor
receptors, fibroblast growth factor
adult
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
FGFR3 Gene Alteration Positive
receptor, fibroblast growth factor, type 3
Alteration of genetic material (finding)
evaluation of the transparency committee
Balversa
erdafitinib
---
https://www.has-sante.fr/jcms/p_3585496/fr/cosidime-dorzolamide-/-timolol
2025
false
false
false
France
dorzolamide hydrochloride-timolol maleate combination
timolol maleate
drug combinations
treatment outcome
insurance, health, reimbursement
glaucoma, open-angle
timolol, combinations
administration, ophthalmic
dorzolamide
evaluation of the transparency committee
dorzolamide hydrochloride
timolol
dorzolamide-timolol combination
---
https://www.has-sante.fr/jcms/p_3585762/fr/perprup-povidone-iodee-/-alcool-isopropylique-antiseptique
2025
false
false
false
France
administration, cutaneous
drug combinations
treatment outcome
insurance, health, reimbursement
antisepsis
adult
adolescent
child
antiseptics and disinfectants
evaluation of the transparency committee
anti-infective agents, local
2-Propanol
povidone-iodine
---
https://www.has-sante.fr/jcms/p_3586458/fr/kayfanda-odevixibat-traitement-du-prurit-cholestatique-associe-au-syndrome-d-alagille
2025
false
false
false
France
Odevixibat sesquihydrate (substance)
cholestatic pruritus in Alagille syndrome
Cholestatic pruritus (disorder)
infant
child
adult
administration, oral
treatment outcome
insurance, health, reimbursement
odevixibat
evaluation of the transparency committee
pruritus
odevixibat
alagille syndrome
---
https://www.has-sante.fr/jcms/p_3586231/fr/adzynma-adamts13r-purpura-thrombotique-thrombocytopenique-congenital-pttc
2025
false
false
false
France
ADAMTS13 Protein
Apadamtase Alfa
enzyme replacement therapy
congenital thrombotic thrombocytopenic purpura
adult
child
treatment outcome
insurance, health, reimbursement
orphan drug production
injections, intravenous
Congenital thrombotic thrombocytopenic purpura
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
---
https://www.has-sante.fr/jcms/p_3586461/fr/bifonazole-substipharm-bifonazole-antifongique-topique
2025
false
false
false
France
administration, cutaneous
insurance, health, reimbursement
treatment outcome
bifonazole
adult
adolescent
child
infant
dermatomycoses
tinea
tinea versicolor
candidiasis, cutaneous
candidiasis, chronic mucocutaneous
Mucocutaneous Candidiasis
evaluation of the transparency committee
bifonazole
antifungal agents
---
https://www.has-sante.fr/jcms/p_3587072/fr/krazati-adagrasib-cancer-bronchique-non-a-petites-cellules
2025
false
false
false
France
adagrasib
KRAS NP_004976.2:p.G12C
KRAS Gene Mutation
evaluation of the transparency committee
adagrasib
carcinoma, non-small-cell lung
---
https://ansm.sante.fr/tableau-acces-derogatoire/adagrasib
2025
false
false
false
France
French
administration, oral
drug information
antineoplastic agents
adagrasib
adagrasib
---
https://ansm.sante.fr/informations-de-securite/celocurine-50-mg-ml-solution-injectable-risques-derreurs-medicamenteuses-graves-clarification-sur-le-volume-des-ampoules
2025
false
false
false
France
French
pharmacovigilance note
medication errors
suxamethonium chloride
injections, intravenous
drug labeling
suxamethonium
---
https://ansm.sante.fr/tableau-acces-derogatoire/versatis
2025
false
false
false
France
French
lidocaine
administration, cutaneous
guidelines for drug use
Peripheral neuropathic pain (finding)
neuralgia
---
https://ansm.sante.fr/tableau-acces-derogatoire/nirogacestat
2025
false
false
false
France
French
administration, oral
nirogacestat
ogsiveo
summary of product characteristics
package leaflet
guidelines for drug use
Desmoid Tumors
Refractory Desmoid Fibromatosis
nirogacestat
---
https://www.has-sante.fr/jcms/p_3587094/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
Locally Advanced Cholangiocarcinoma
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
ivosidenib
adult
Metastatic Cholangiocarcinoma
IDH1 NP_005887.2:p.R132X
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
administration, oral
antineoplastic agents
evaluation of the transparency committee
ivosidenib
---
https://www.has-sante.fr/jcms/p_3589090/fr/tiotropium-eg-vertical-haler-tiotropium-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
powders
treatment outcome
insurance, health, reimbursement
administration, inhalation
tiotropium bromide
evaluation of the transparency committee
pulmonary disease, chronic obstructive
Tiotropium Bromide
---
https://www.has-sante.fr/jcms/p_3527462/fr/retsevmo-selpercatinib-cancer-de-la-thyroide
2025
false
false
false
France
adult
adolescent
treatment outcome
insurance, health, reimbursement
administration, oral
selpercatinib
advanced RET fusion-positive thyroid cancer
RET Fusion Positive
thyroid cancer, medullary
carcinoma, neuroendocrine
Advanced Thyroid Gland Medullary Carcinoma
RET Inhibitor
antineoplastic agents
evaluation of the transparency committee
selpercatinib
thyroid neoplasms
---
https://ansm.sante.fr/tableau-acces-derogatoire/idhifa
2025
false
false
false
France
French
enasidenib
administration, oral
Product containing only enasidenib in oral dose form (medicinal product form)
technical report
guidelines for drug use
summary of product characteristics
---
https://ansm.sante.fr/tableau-acces-derogatoire/vyjuvek
2025
false
false
false
France
French
insurance, health, reimbursement
Beremagene Geperpavec
beremagene geperpavec
drug information
continuity of patient care
guidelines for drug use
administration, cutaneous
epidermolysis bullosa dystrophica
epidermolysis bullosa dystrophica
infant
child
COL7A1 Gene Mutation
summary of product characteristics
package leaflet
gene therapy
---
https://www.has-sante.fr/jcms/p_3588817/fr/iqirvo-elafibranor-cholangite-biliaire-primitive
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
Primary Biliary Cholangitis
drug therapy, combination
ursodeoxycholic acid
adult
elafibranor
evaluation of the transparency committee
elafibranor
---
https://www.has-sante.fr/jcms/p_3589751/fr/agilus-dantrolene-sodique-hemiheptahydrate-anesthesie
2025
false
false
false
France
Dantrolene sodium, hemiheptahydrate
insurance, health, reimbursement
treatment outcome
adult
child
adolescent
Malignant hyperpyrexia caused by anesthetic (disorder)
anesthetics
malignant hyperthermia
infant
dantrolene
Product containing only dantrolene in parenteral dose form (medicinal product form)
evaluation of the transparency committee
Dantrolene Sodium
dantrolene
---
https://www.has-sante.fr/jcms/p_3589935/fr/kinox-monoxyde-d-azote-vasodilatateur-inhale
2025
false
false
false
France
adult
infant, newborn
adolescent
child
infant
nitric oxide
perioperative pulmonary hypertension
postoperative pulmonary hypertension
cardiac surgical procedures
evaluation of the transparency committee
nitric oxide
administration, inhalation
hypertension, pulmonary
respiratory distress syndrome, newborn
---
https://www.has-sante.fr/jcms/p_3590642/fr/pepaxti-melphalan-flufenamide-myelome-multiple
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
phenylalanine
antineoplastic agents
melphalan flufenamide
antineoplastic combined chemotherapy protocols
Dexamethasone/Melphalan Flufenamide Regimen
Triple-Class Refractory Multiple Myeloma
evaluation of the transparency committee
melflufen
multiple myeloma
melphalan
---
https://www.has-sante.fr/jcms/p_3591339/fr/ofriri-dorzolamide-hypertonie-oculaire-glaucome-a-angle-ouvert-glaucome-pseudo-exfoliatif
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, ophthalmic
ocular hypertension
exfoliation syndrome
dorzolamide
evaluation of the transparency committee
glaucoma, open-angle
dorzolamide
---
https://www.has-sante.fr/jcms/p_3591600/fr/olatalin-dorzolamide/timolol-glaucome-a-angle-ouvert-glaucome-pseudo-exfoliatif
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
dorzolamide-timolol combination
dorzolamide
timolol
drug combinations
administration, ophthalmic
timolol, combinations
evaluation of the transparency committee
exfoliation syndrome
glaucoma, open-angle
---
https://www.has-sante.fr/jcms/p_3590911/fr/glucose-aguettant-glucose-solute
2025
false
false
false
France
infusions, intravenous
insurance, health, reimbursement
treatment outcome
carbohydrates
evaluation of the transparency committee
glucose
---
https://www.has-sante.fr/jcms/p_3590636/fr/imfinzi-durvalumab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
durvalumab
antineoplastic combined chemotherapy protocols
Mismatch Repair Deficiency
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
infusions, intravenous
evaluation of the transparency committee
durvalumab
endometrial neoplasms
---
https://www.has-sante.fr/jcms/p_3591345/fr/relistor-bromure-de-methylnaltrexone-constipation-liee-aux-opioides
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
methylnaltrexone bromide
injections, subcutaneous
adult
evaluation of the transparency committee
Opioid-Induced Constipation
methylnaltrexone
naltrexone methylbromide
---
https://www.has-sante.fr/jcms/p_3590639/fr/imfinzi-lynparza-durvalumab/olaparib-cancer-de-l-endometre
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
insurance, health, reimbursement
treatment outcome
Antineoplastic Agents, Immunological
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Mismatch Repair Proficient
Mismatch Repair Deficiency
durvalumab
durvalumab
olaparib
olaparib
evaluation of the transparency committee
endometrial neoplasms
---
https://www.cbip.be/fr/articles/4491?folia=4486
2025
false
false
false
Belgium
French
aged
journal article
drug information
drug interactions
analgesics, opioid
Cytochrome P-450 CYP2D6 Inhibitors
Pharmacokinetics: Drug Interactions
antidepressive agents
---
https://ansm.sante.fr/actualites/fluoroquinolones-nous-rappelons-limportance-du-bon-usage-de-ces-antibiotiques
2025
false
false
false
France
French
guidelines for drug use
fluoroquinolones
fluoroquinolones
anti-bacterial agents
anti-bacterial agents
administration, oral
injections
fluoroquinolones
Off-Label use
drug interactions
technical report
pharmacovigilance
france
Drug-Related side effects and adverse reactions
ciprofloxacin
levofloxacin
ofloxacin
norfloxacin
Moxifloxacin
lomefloxacin
delafloxacin
---
https://www.has-sante.fr/jcms/p_3592985/fr/elahere-mirvetuximab-soravtansine-cancer-de-l-ovaire
2025
false
false
false
France
insurance, health, reimbursement
mirvetuximab soravtansine
infusions, intravenous
adult
fallopian tube neoplasms
peritoneal neoplasms
Folate Receptor Alpha Positive
evaluation of the transparency committee
ovarian neoplasms
mirvetuximab soravtansine
---
https://ansm.sante.fr/tableau-acces-derogatoire/tepezza
2025
false
false
false
France
French
summary of product characteristics
guidelines for drug use
insurance, health, reimbursement
tepezza
teprotumumab
teprotumumab
graves ophthalmopathy
graves disease
myxedema
infusions, intravenous
---
https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
concizumab
concizumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/afqlir
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
aflibercept
aflibercept
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/opuviz
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
aflibercept
aflibercept
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/eltrombopag-viatris
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
eltrombopag
eltrombopag
drugs, generic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/imuldosa
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/absimky
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/eksunbi
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals
---
https://www.has-sante.fr/jcms/p_3599701/fr/beclometasone-formoterol-biogaran-beclometasone-/-formoterol-asthme-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, inhalation
formoterol and beclometasone
evaluation of the transparency committee
asthma
beclomethasone
pulmonary disease, chronic obstructive
Formoterol Fumarate
---
https://www.has-sante.fr/jcms/p_3599704/fr/ferrostrane-nourrissons-feredetate-de-sodium-carence-martiale
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
pharmaceutical solutions
administration, oral
sodium feredetate
evaluation of the transparency committee
Iron Deficiencies
ferric sodium edetate
infant
Fe(III)-EDTA
---
https://www.cbip.be/fr/articles/4528?folia=4520
2025
false
false
false
Belgium
French
journal article
pharmacovigilance note
drug interactions
anti-inflammatory agents, non-steroidal
cholinesterase inhibitors
risk
aged
peptic ulcer
alzheimer disease
---
https://ansm.sante.fr/dossiers-thematiques/bon-usage-des-benzodiazepines
2025
false
false
false
France
French
guidelines for drug use
patients guideline
benzodiazepines
directory
---
https://www.has-sante.fr/jcms/p_3601431/fr/ajovy-fremanezumab-migraine
2025
false
false
false
France
migraine disorders
insurance, health, reimbursement
treatment outcome
fremanezumab
injections, subcutaneous
antibodies, monoclonal
adult
calcitonin gene-related peptide
evaluation of the transparency committee
fremanezumab
---
https://www.has-sante.fr/jcms/p_3601952/fr/seladelpar-gilead-seladelpar-lysine-dihydrate-cholangite-biliaire-primitive
2025
false
false
false
France
Seladelpar Lysine
Seladelpar lysine dihydrate
Primary Biliary Cholangitis
evaluation of the transparency committee
lysine
seladelpar
---
https://www.has-sante.fr/jcms/p_3601988/fr/pedmarqsi-thiosulfate-de-sodium-prevention-de-l-ototoxicite-du-cisplatine
2025
false
false
false
France
Drug-Induced Ototoxicity
Ototoxicity
cisplatin
infant
adolescent
child
evaluation of the transparency committee
thiosulfates
sodium thiosulfate
---
https://www.afmps.be/fr/news/les_medicaments_de_therapie_innovante_non_reglementes_presentent_de_graves_risques_pour_la
2025
false
false
false
Belgium
French
innovative therapies
risk
patient safety
pharmacovigilance note
Dendritic Cell Therapy
immunotherapy, adoptive
dendritic cells
legislation, drug
europe
belgium
---
https://www.has-sante.fr/jcms/p_3601719/fr/elahere-mirvetuximab-soravtansine-cancer-de-l-ovaire
2025
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
mirvetuximab soravtansine
mirvetuximab soravtansine
adult
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
evaluation of the transparency committee
Folate Receptor Alpha Positive
---
https://www.ema.europa.eu/en/medicines/human/EPAR/agilus
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
dantrolene
Dantrolene sodium, hemiheptahydrate
Dantrolene sodium, hemiheptahydrate
dantrolene
dantrolene
malignant hyperthermia
muscle relaxants, central
muscle relaxants, central
injections, intravenous
risk management
drug interactions
pregnancy
breast feeding
ryanodine receptor 1
ryanodine receptor calcium release channel
drug evaluation, preclinical
---
https://www.cochrane.org/fr/CD001155/CENTRALED_lalendronate-previent-il-les-fractures-causees-par-losteoporose-chez-les-femmes-post-menopausees
2025
false
United Kingdom
France
French
meta-analysis
osteoporosis, postmenopausal
osteoporotic fractures
alendronate
treatment outcome
bone density conservation agents
french abstract
---
http://www.cochrane.org/fr/CD001703
2025
false
United Kingdom
France
French
meta-analysis
low back pain
antidepressive agents
treatment outcome
low back pain
french abstract
---
https://www.has-sante.fr/jcms/p_3598324/fr/otezla-apremilast-psoriasis-en-plaques-modere-a-severe-chez-les-enfants-et-adolescents-a-partir-de-6-ans
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
apremilast
administration, oral
evaluation of the transparency committee
child
psoriasis
apremilast
adolescent
---
https://www.has-sante.fr/jcms/p_3598809/fr/phelinun-melphalan-cancer-et-greffe
2025
false
false
false
France
Melphalan Hydrochloride
hematopoietic stem cell transplantation
hematologic diseases
infusions, intravenous
insurance, health, reimbursement
treatment outcome
multiple myeloma
hodgkin disease
lymphoma, Non-Hodgkin
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, myeloid, acute
neuroblastoma
Childhood Neuroblastoma
melphalan
evaluation of the transparency committee
melphalan
transplantation conditioning
---
https://www.has-sante.fr/jcms/p_3598812/fr/nordimet-methotrexate-psoriasis-en-plaque-modere
2025
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
injections, subcutaneous
methotrexate
evaluation of the transparency committee
psoriasis
methotrexate
---
https://ansm.sante.fr/actualites/clozapine-une-prescription-initiale-desormais-possible-en-ville
2025
false
false
false
France
French
urban health services
drug prescriptions
Upfront Treatment
clozapine
antipsychotic agents
clozapine
drug information
legislation, pharmacy
---
https://www.ema.europa.eu/en/medicines/human/EPAR/paxneury
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
guanfacine
guanfacine
attention deficit disorder with hyperactivity
child
adolescent
Attention deficit disorder of childhood without mention of hyperactivity
drugs, generic
continuity of patient care
administration, oral
tablets
Product containing only guanfacine in oral dose form (medicinal product form)
guanfacine hydrochloride
guanfacine hydrochloride
Delayed-Action preparations
Product containing precisely guanfacine (as guanfacine hydrochloride) 1 milligram/1
each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 2 milligram/1
each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 3 milligram/1
each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 4 milligram/1
each prolonged-release oral tablet (clinical drug)
drug monitoring
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
receptor, adrenergic, alpha-2A
Alpha-2 adrenergic receptor agonist (disposition)
---
https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
lazertinib
lazertinib
drug approval
europe
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
lazertinib
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
adult
carcinoma, non-small-cell lung
antineoplastic agents
antineoplastic agents
carcinoma, non-small-cell lung
mutation
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
antineoplastic combined chemotherapy protocols
amivantamab
Amivantamab/Lazertinib Regimen
administration, oral
Drug-Related side effects and adverse reactions
venous thromboembolism
EGF Receptors
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Lazertinib Mesylate Monohydrate
Lazertinib Mesylate Monohydrate
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kavigale
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
Sipavibart
drug approval
europe
Sipavibart
sipavibart
adolescent
adult
immunocompromised host
COVID-19
infusions, intravenous
injections, intramuscular
Anti-spike Protein SARS-CoV-2 Monoclonal Antibody
antibodies, monoclonal
antibodies, monoclonal
product surveillance, postmarketing
Pre-Exposure Prophylaxis
---
https://www.ema.europa.eu/en/medicines/human/EPAR/yesintek
2025
false
false
false
Netherlands
French
English
Ustekinumab
Ustekinumab
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
---
https://www.ema.europa.eu/en/medicines/human/EPAR/baiama
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept
---
https://www.ema.europa.eu/en/medicines/human/EPAR/gohibic
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilobelimab
vilobelimab
drug approval
europe
vilobelimab
antibodies, monoclonal
antibodies, monoclonal
complement inactivating agents
complement inactivating agents
COVID-19
COVID-19-Associated Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome
infusions, intravenous
product surveillance, postmarketing
complement C5a
adult
drug evaluation, preclinical
pregnancy
breast feeding
---
https://www.ema.europa.eu/en/medicines/human/EPAR/augtyro
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
repotrectinib
repotrectinib
antineoplastic agents
antineoplastic agents
drug approval
europe
repotrectinib
adult
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
ROS1 Fusion Gene Positive
Advanced Lung Non-Small Cell Carcinoma
adolescent
NTRK Fusion Gene Positive
Solid Neoplasm
Solid Neoplasm
administration, oral
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Anaplastic Lymphoma Kinase
ROS1 protein, human
receptor, trkc
receptor, trkb
receptor, trka
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ahzantive
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept
---
https://www.ema.europa.eu/en/medicines/human/EPAR/eydenzelt
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept
---
https://www.ema.europa.eu/en/medicines/human/EPAR/emcitate
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
3,3',5-triiodothyroacetic acid
3,3',5-triiodothyroacetic acid
orphan drug production
tiratricol
drug approval
europe
triiodothyronine
thyrotoxicosis
Allan-Herndon-Dudley Syndrome
administration, oral
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/zefylti
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Filgrastim
Filgrastim
---
https://www.ema.europa.eu/en/medicines/human/EPAR/obodence
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Denosumab
Denosumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/nemluvio
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
nemolizumab
nemolizumab
drug approval
europe
nemolizumab
adult
adolescent
dermatitis, atopic
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
Prurigo nodularis (disorder)
injections, subcutaneous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
IL31RA protein, human
receptors, interleukin
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
catumaxomab
catumaxomab
catumaxomab
drug approval
europe
product surveillance, postmarketing
antibodies, bispecific
antibodies, bispecific
Malignant Peritoneal Effusion
ascites
EPCAM protein, human
Epithelial Cell Adhesion Molecule
Intra-Abdominal infusions
T-cell Engaging Bispecific Antibody
adult
pregnancy
breast feeding
CD3 Complex
---
https://www.ema.europa.eu/en/medicines/human/EPAR/andembry
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Garadacimab
Garadacimab
drug approval
europe
garadacimab
angioedemas, hereditary
adult
adolescent
Hereditary angioedema attack
injections, subcutaneous
risk management
product surveillance, postmarketing
antibodies, monoclonal
antibodies, monoclonal
pregnancy
breast feeding
factor xiia
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/beyonttra
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
treatment outcome
Acoramidis
Acoramidis
Acoramidis Hydrochloride
Acoramidis Hydrochloride
acoramidis
drug approval
europe
product surveillance, postmarketing
administration, oral
amyloidosis, hereditary, Transthyretin-Related
Hereditary ATTR amyloidosis
Wild type ATTR amyloidosis
adult
amyloidosis
cardiomyopathies
drug interactions
Pharmacological Chaperone
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rytelo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Imetelstat Sodium
Imetelstat Sodium
imetelstat
imetelstat
drug approval
europe
imetelstat
myelodysplastic syndromes
anemia
adult
orphan drug production
infusions, intravenous
Telomerase Inhibitor
Telomerase Inhibitor
telomerase
product surveillance, postmarketing
Antisense Oligonucleotides
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/wainzua
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
eplontersen
eplontersen
drug approval
europe
eplontersen
amyloidosis, hereditary, Transthyretin-Related
adult
injections, subcutaneous
oligonucleotides, antisense
oligonucleotides, antisense
risk management
eplontersen sodium
eplontersen sodium
product surveillance, postmarketing
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/hetronifly
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Serplulimab
Serplulimab
drug approval
europe
antibodies, monoclonal
antibodies, monoclonal
serplulimab
small cell lung carcinoma
neoplasm metastasis
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
carboplatin
etoposide
infusions, intravenous
programmed cell death 1 receptor
risk management
product surveillance, postmarketing
Extensive Stage Lung Small Cell Carcinoma
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/yuvanci
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
drug combinations
macitentan
macitentan
macitentan and tadalafil
Tadalafil
Tadalafil
drug approval
europe
adult
hypertension, pulmonary
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
phosphodiesterase 5 inhibitors
administration, oral
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/obgemsa
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
vibegron
vibegron
drug approval
europe
vibegron
urinary bladder, overactive
adult
administration, oral
product surveillance, postmarketing
pregnancy
breast feeding
adrenergic beta-3 receptor agonists
adrenergic beta-3 receptor agonists
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/eribulin-baxter
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
eribulin mesylate
eribulin mesylate
drugs, generic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-accord
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
pomalidomide
pomalidomide
drugs, generic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/avzivi
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Bevacizumab
Bevacizumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accord-healthcare
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Dasatinib
Dasatinib
drugs, generic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/fymskina
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/otulfi
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals
---
